Get the Stockscreener App
14.12
0.64%
0.09
Pre-market:
14.00
-0.12
-0.85%
Liquidia Corp stock is traded at $14.12, with a volume of 584.67K.
It is up +0.64% in the last 24 hours and down -9.49% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$14.03
Open:
$13.89
24h Volume:
584.67K
Relative Volume:
0.62
Market Cap:
$1.13B
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-11.77
EPS:
-1.2
Net Cash Flow:
$-52.85M
1W Performance:
+2.92%
1M Performance:
-9.49%
6M Performance:
+28.25%
1Y Performance:
+14.15%
1-Day Range:
$13.69
$14.13
1-Week Range:
$13.11
$14.22
52-Week Range:
$8.26
$16.81
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
14.12 | 1.13B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Was anything positive for Liquidia Corp (LQDA) stock last session? - uspostnews.com
Liquidia Corp files patent infringement suit against United Therapeutics By Investing.com - Investing.com Canada
Liquidia Corp files patent infringement suit against United Therapeutics - Investing.com
Liquidia Sues UTC Seeking Patent Damages for Tyvaso DPI Drug (1) - Bloomberg Law News
Liquidia Corp’s chief medical officer sells $50,398 in stock By Investing.com - Investing.com Canada
Liquidia Corp Executives Sell Shares Under Rule 10b5-1 Plan - TradingView
Liquidia Corp’s chief medical officer sells $50,398 in stock - Investing.com
Liquidia Corp’s chief business officer Jason Adair sells shares worth $25,185 - Investing.com India
Great week for Liquidia Corporation (NASDAQ:LQDA) institutional investors after losing 1.5% over the previous year - Yahoo Finance
Breaking Down Liquidia: 4 Analysts Share Their Views - Benzinga
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch - Investing.com Australia
Liquidia at Needham Conference: Strategic Insights on Eutropia Launch By Investing.com - Investing.com India
Liquidia: United Therapeutics Has The Last Laugh (LQDA) - Seeking Alpha
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Liquidia (NASDAQ:LQDA) - Defense World
Liquidia Corp (LQDA) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
UPDATELiquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Liquidia Technologies (LQDA) Receives a Buy from Scotiabank - The Globe and Mail
Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Average Price Target from Analysts - The AM Reporter
Liquidia says its request for Yutrepia final approval undergoes FDA review - MSN
Liquidia stock rises as Yutrepia undergoes FDA review (LQDA) - Seeking Alpha
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder - Investing.com
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA - TipRanks
FDA accepts Liquidia’s resubmission for YUTREPIA inhalation powder By Investing.com - Investing.com Canada
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - The Manila Times
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
Liquidia Corporation (NASDAQ:LQDA) Q4 2024 Earnings Call Transcript - Insider Monkey
Liquidia (NASDAQ:LQDA) Price Target Raised to $34.00 - Defense World
Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result - GuruFocus.com
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects By Investing.com - Investing.com South Africa
What 4 Analyst Ratings Have To Say About Liquidia - Benzinga
Scotiabank raises Liquidia stock target to $34 on Yutrepia prospects - Investing.com
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Raymond James maintains strong buy on Liquidia stock, $27 target - Investing.com
H.C. Wainwright maintains Buy on Liquidia stock, $29 target - Investing.com
Raymond James maintains strong buy on Liquidia stock, $27 target By Investing.com - Investing.com UK
Liquidia Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Liquidia Corp (LQDA) - GuruFocus
Earnings call transcript: Liquidia Technologies Q4 2024 misses revenue forecast - Investing.com
Liquidia Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Liquidia Corp Reports Annual EPS of -$1.66 and Revenue of $14.0 Million, Missing Estimates - GuruFocus.com
Liquidia Corp SEC 10-K Report - TradingView
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update - TradingView
Liquidia Technologies earnings missed by $0.07, revenue fell short of estimates - Investing.com
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million - The Manila Times
When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable? - Simply Wall St
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):